NAD⁺ Therapy – Patient FAQ

This therapy will be available from the 26th January 2026.
In practice: First consult plus SCI (15Min)
Booking is Essential

❓ What is NAD⁺ ?
NAD⁺ (Nicotinamide Adenine Dinucleotide) is a naturally occurring co-enzyme essential for cellular energy (ATP), DNA repair, brain function, and metabolic health.

❓ Is NOVA NAD⁺ bioavailable?
✅ Yes. NOVA NAD⁺ is bioavailable and effectively utilised by the body when administered subcutaneously.

❓ Is NOVA NAD⁺ vegan?
✅ Yes. NOVA NAD⁺ is 100% vegan.

❓ Does NOVA NAD⁺ contain any additives or preservatives?
🚫 No. NOVA NAD⁺ contains no additives, fillers, or preservatives.

❓ Is your NAD⁺ pharmaceutical grade?
✅ Yes. Our NAD⁺ is pharmaceutical grade, meeting high purity and safety standards.

❓ Why choose subcutaneous NAD⁺ instead of oral supplements?
Subcutaneous NAD⁺:

  • Bypasses the digestive system
  • Higher and more predictable absorption
  • Direct systemic availability
  • Suitable for patients with gut absorption issues
  • More effective for fatigue, neurological, and metabolic support

Oral NAD⁺ precursors: • Must convert in the gut and liver

  • Lower and variable absorption
  • Slower and less reliable clinical response
    ➡️ Subcutaneous delivery allows greater bioavailability and clinical effectiveness compared to oral forms.

❓ Can NAD⁺ be used at home?
✅ Yes. Home-use pen systems are available after clinical assessment and proper instruction.

❓ How often will I need NAD⁺ injections?
This is individualised. Some patients benefit from a short loading phase followed by maintenance dosing.
First loading phase daily
There after 2 to 3 x a week depending on needs.
Then weekly and finally maintenance doses

❓ Are there side effects?
Mild, temporary effects may include headache, flushing, fatigue, or slight injection site discomfort, particularly during early doses.

❓ Who should not use NAD⁺ therapy?
Pregnant or breastfeeding patients, individuals with active cancer, or severe liver or kidney disease unless under specialist supervision.

Share this Article

Facebook
Pinterest
Twitter
LinkedIn